Physician profile
Jane Sunoo
NPI 1083673040
$2,562.06
in general payments reported to CMS, 2019-2025
28 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $442 · 2021: $666 · 2022: $404 · 2023: $332 · 2024: $296 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $648.23 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $265.09 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $167.42 | 2019-2022 | |
| Abbott Laboratories | $127.62 | 2021-2024 | Freestyle Libre 2, Octrode |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.24 | 2020-2022 | |
| Amarin Pharma, INC. | $110.80 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $100.86 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $97.63 | 2020-2021 | |
| Lilly USA, LLC | $94.79 | 2020-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $78.42 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $75.46 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $72.30 | 2019-2020 | |
| Dexcom, INC. | $71.27 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $69.29 | 2021-2022 | |
| Biogen, INC. | $46.83 | 2024 | Leqembi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.61 | 2025 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $44.46 | 2020 | |
| Adlon Therapeutics L.P. | $44.37 | 2020-2021 | |
| Eisai INC. | $40.71 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $38.70 | 2020-2025 | Camzyos |
| Otsuka America Pharmaceutical, INC. | $38.26 | 2021-2023 | Rexulti |
| Bausch Health US, LLC | $35.70 | 2020-2022 | |
| Exact Sciences Corporation | $30.14 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $20.52 | 2024 | Voquezna |
| Inspire Medical Systems, INC. | $19.59 | 2024 | Inspire |
| Jazz Pharmaceuticals INC. | $19.41 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $18.46 | 2023 | Breztri |
| Circassia INC. | $15.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Sunoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.